Characterization of the ubiquitylating components of the human malaria parasite's protein degradation pathway. by Chung, Duk-Won D et al.
UC Riverside
UC Riverside Previously Published Works
Title
Characterization of the ubiquitylating components of the human malaria parasite's protein 
degradation pathway.
Permalink
https://escholarship.org/uc/item/38w2x8zp
Journal
PloS one, 7(8)
ISSN
1932-6203
Authors
Chung, Duk-Won D
Ponts, Nadia
Prudhomme, Jacques
et al.
Publication Date
2012
DOI
10.1371/journal.pone.0043477
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Characterization of the Ubiquitylating Components of
the Human Malaria Parasite’s Protein Degradation
Pathway
Duk-Won D. Chung1, Nadia Ponts1,2, Jacques Prudhomme1, Elisandra M. Rodrigues1, Karine G. Le Roch1*
1Department of Cell Biology and Neuroscience, University of California Riverside, Riverside, California, United States of America, 2 INRA, MycSA UR 1264, BP81, 33883
Villenave d’Ornon Cedex, France
Abstract
Ubiquitin-dependent protein degradation within malarial parasites is a burgeoning field of interest due to several
encouraging reports of proteasome inhibitors that were able to confer antimalarial activity. Despite the growing interest in
the Plasmodium proteasome system, relatively little investigation has been done to actually characterize the parasite
degradation machinery. In this report, we provide an initial biological investigation of the ubiquitylating components of the
endoplasmic reticulum-associated degradation (ERAD) system, which is a major pathway in targeting misfolded proteins
from the ER to the cytosol for proteasome degradation. We are able to show that the ERAD system is essential for parasite
survival and that the putative Plasmodium HRD1 (E3 ubiquitin ligase), UBC (E2 ubiquitin conjugating enzyme) and UBA1 (E1
ubiquitin activating enzyme) are able to mediate in vitro ubiquitylation. Furthermore, by using immunofluorescence, we
report that Plasmodium HRD1 localizes to the ER membranes, while the Plasmodium UBC and UBA1 localize to the cytosol.
In addition, our gene disruption experiments indicate that the Plasmodium HRD1 is likely essential. We have conducted an
initial characterization of the ubiquitylating components of the Plasmodium ERAD system, a major pathway for protein
degradation and parasite maintenance. In conjunction with promising proteasome inhibitor studies, we explore the
possibility of targeting the Plasmodium ERAD system for future bottom-up drug development approaches.
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Introduction
Malaria is one of the deadliest infectious diseases of the world,
infecting up to half a billion and killing up to one million people
each year [1]. Though progresses were made in combating
malaria with multi-drug therapies [2], the high-cost treatment and
the rise of drug resistances beckon the need for novel and cheap
antimalarials. The causative agents of malaria are protozoan
parasites that belong to the genus Plasmodium. Among them,
Plasmodium falciparum is the deadliest human-infecting species. With
the urgent need of developing new anti-malarial therapies, there
has been much effort in understanding how the Plasmodium
regulates its life cycle to subsequently identify potential new targets
for drug development and therapeutic intervention.
In recent years, several studies showed that proteasome
inhibitors have significant antimalarial properties [3–7] (see [8]
for a review). Previous studies characterized some of P. falciparum’s
26S proteasome components [9,10] and a bacteria-like protea-
some [11–13], both involved in protein degradation. Though the
protein degradation via the 26S proteasome closely involves
ubiquitylation of target substrates, very little work has been done
regarding the characterization of the parasite’s ubiquitylating
machinery acting upstream of the proteasome, possibly leading to
the discovery of parasite-specific divergences that can be exploited
for drug targeting. In eukaryotes, the endoplasmic reticulum-
associated degradation (ERAD) pathway mediates protein degra-
dation during quality control. Aberrant proteins are recognized by
ER luminal chaperone proteins and protein disulfide isomerases to
help discriminate properly folded proteins from misfolded proteins
[14]. Misfolded proteins are shuttled to the DER1 translocon
complex, which forms a hydrophobic pore to allow the retro-
translocation of proteins through the ER membrane. Within this
translocon complex, the HRD1 E3 ubiquitin ligase interacts with
membrane-bound proteins needed for retro-translocation and
helps form the hydrophobic pore complex [15]. The HRD1 E3
enzyme also catalyzes, with the intervention of other ubiquitylating
enzymes, the ubiquitylation of the target misfolded protein that is
the prerequisite for subsequent retro-translocation to the cytosol
and destruction by the 26S proteasome [16–18]. Typically,
ubiquitylation involves the covalent attachment of a ubiquitin
moiety to lysine residues of protein substrates via the hierarchical
intervention of an E1 ubiquitin-activating enzyme, an E2
ubiquitin-conjugating enzyme, and an E3 ubiquitin ligase that is
usually involved in specific substrate recognition [19,20]. Up until
now, no functional study has investigated the ubiquitylating
components that compose the malaria parasite ERAD pathway.
While ubiquitin E1 and E2 enzymes seem to be well conserved
across eukaryotic phyla, Plasmodium E3 ubiquitin ligases have been
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shown to have high levels of divergences that can be utilized for
the development of new antimalarials [21].
Here, we present the identification and biochemical character-
ization of the ubiquitylating components of the P. falciparum ERAD
system: one ubiquitin-activating E1 enzyme, an ubiquitin-conju-
gating E2 enzyme, and an ubiquitin E3 ligase. Our results show
that the Plasmodium ERAD system is vital to the parasite and that
recombinant E1, E2, and E3 enzymes promote ubiquitylation in
vitro. Furthermore, immunofluorescence microscopy experiments
also reveal that E1 and E2 localize to the cytosol whereas the E3
ubiquitin ligase is found within the ER membrane, consistent with
their respective functions in the ERAD pathway. Finally, gene
disruption experiments suggest that the ubiquitylating components
of the Plasmodium ERAD system are essential to the parasite
survival. This analysis contributes to our understanding of the
mechanisms leading to protein degradation in the human malaria
parasite and proposes the components of the ERAD pathway as
potential targets for the ‘bottom-up’ development of new drugs.
Results
ERAD-specific Inhibitor Eeyarestatin I Validates the
Essentiality of an Ubiquitin-dependent ERAD System in
Plasmodium
To test the essentiality of the ERAD pathway in Plasmodium, we
decided to test the inhibitory effects on P. falciparum cultures with
Eeyarestatin I (ESI). ESI a known ERAD inhibitor which acts to
block the release of ubiquitylated misfolded proteins from the
Sec61 translocon at the ER membrane [22,23] thus preventing
misfolded proteins from reaching the proteasome. P. falciparum
parasites were found to be highly sensitive to ESI, with an IC50 of
3.541561.0399 mM (Figure 1A). In addition, we validated ESI’s
ability to block the Plasmodium ERAD system by analyzing changes
in the levels of ubiquitylated substrates between untreated and
treated cultures. Parasites that were treated with ESI were found to
have heightened abundances of ubiquitylated proteins (Figure 1B).
The observed accumulation of ubiquitylated proteins is likely the
result of ESI preventing the translocation of ubiquitylated
misfolded proteins across the ER membrane for degradation as
seen in other organisms [23]. These ESI studies give preliminary
indication that Plasmodium does indeed contain an ubiquitin-
dependent ERAD system that is integral to parasite survival.
In silico Analysis of the Plasmodium ERAD Ubiquitylating
Components
The P. falciparum genome was scanned to identify candidates for
the ubiquitylating components of the ERAD system based on
sequence homology and domain architecture using a previously
published approach [21]. We identified PFL1245w as the putative
PfUba1 E1 ubiquitin enzyme, PFL0190w, as the putative PfUbc7
E2 ubiquitin conjugating enzyme, and PF14_0215 as a putative
E3 ubiquitin ligase with distant protein homology with the human
and yeast HRD1.
Similar to yeast and human UBA1, the 1140 amino acid (aa)
long Plasmodium protein encoded by PFL1245w contains a
ubiquitin-activating enzyme active site, two ubiquitin-like activat-
ing enzyme catalytic domains, two ThiF repeats, and a catalytic
cysteine at the N-terminal end (Figure 2A). The short protein
(147 aa in length) encoded by PFL0190w has strong homology to
the human and yeast UBC7 and contains an ubiquitin conjugating
enzyme domain taking up almost its whole length (Figure 2A).
Finally, the protein encoded by PF14_0215 presents some
sequence similarities with the canonical HRD1 of the ERAD
pathway in eukaryotic models [21,24,25]. Similar to HRD1,
PF14_0215 has multiple transmembrane domains, an E3 RING
zinc finger (zf-C3HC4) domain on its C-terminal half, and a
predicted signal peptide consistent with ER targeting (Figure 2A).
The presence of four transmembrane domains is compatible with
an ability to form pores to participate in the recognition and
translocation of misfolded proteins across the ER membrane.
Based on protein alignments, we show that the PF14_0215 protein
contains a highly conserved zf-C3HC4 domain (289–336 aa)
similar to that of other characterized HRD1 proteins from various
eukaryotic model systems (Figure 2B).
Based on our in silico predictions, it is likely that these proteins
have the necessary components to promote ubiquitylation and
have enough homology to the human and yeast ERAD
components to be part of the parasite’s ERAD system. In the
following sections, we conduct some initial biological character-
izations to validate our in silico data analyses.
PF14_0215 is an Essential ER Membrane-bound E3
Ubiquitin Ligase
Initiating our biological validation, we investigated the bio-
chemical activity and the cellular localization of the protein
encoded PF14_0215. First, the predicted RING domain of
PF14_0215 was cloned into E. coli, fused to tandem GST and
6xHis tags, expressed, and purified (Figure 3A and Figure S1). In
vitro ubiquitylation assays were performed by incubating the
purified recombinant PF14_0215 RING domain with commer-
cially available human E1 (UBA1), various human E2 (UBC)
enzymes, and commercial purified ubiquitin (Figure 3B). Anti-
ubiquitin immunoblots show that different patterns of ubiquityla-
tion were obtained when our recombinant E3 and the commercial
E1 were mixed with UBCH5a, UBCH6, or UBCH13complex. With
UBCH5a, recombinant PF14_0215 RING domain elicited a
laddering effect that mostly began from the 50 kDa range, while
with UBCH13, the ubiquitin laddering began around the 15 kDa
mark. Ubiquitylation was no longer detected when our recombi-
nant PF14_0215 was removed from the assay (Figure 3C), which
demonstrates that PF14_0215 promotes ubiquitylation. We
investigated further the differences in ubiquitylating patterns
obtained when different E2 enzymes are used. Anti-GST
immunoblots of our in vitro ubiquitylation products were
performed to distinguish auto-ubiquitylation events, a character-
istic of RING E3 ligases, from the production of free poly-
ubiquitin tails (Figure 3D). The high molecular weight banding
pattern that was obtained in the presence of UBCH5a indicates
the auto poly-ubiquitylation of our epitope-tagged PF14_0215. On
the contrary, the single 8 kDa molecular weight shift of
recombinant PF14_0215 obtained in the presence of UBCH6
indicates that only mono-ubiquitylation occurs. Finally, no auto-
ubiquitylation of PF14_0215 was detected in the presence of
UBCH13complex (pattern not different from what obtained with
our E3 alone). The previously observed pattern of ubiquitylation
consisted of free poly-ubiquitin tails only (Figure 3B). Taken
together, our results demonstrate that PF14_0215 is a genuine E3
ubiquitin ligase that catalyzes both the formation of poly-ubiquitin
tails and its auto-ubiquitylation.
We further investigated the possible role of PF14_0215 E3 ligase
and determined its localization by immunofluorescence microsco-
py using custom antibodies. We first verified the specificity of the
custom antibody against PF14_0215 (see figure S2). Then we used
the custom antibody to immuno-stain PF14_0215, which was
found to co-localize with Plasmepsin V, a Plasmodium protein
known to reside in the ER membrane [26] (Figure 4A). Co-imaged
with DAPI-stained nuclei and ACP-GFP, an apicoplast marker,
for comparative purposes, PF14_0215 was observed at various
Ubiquitin-Dependent ERAD System in Plasmodium
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stages of the parasite life cycle and was found within reticular
structures outside the nuclear regions at the trophozoite and
schizont stages of the parasite, similar to the physical attributes of
the ER (Figure 4B). In the late schizont stage PF14_0215 proteins
reside within globular structures surrounding each budding
merozoite in a pattern typical of the ER (Figure 4B). These
observations support that PF14_0215 E3 ubiquitin ligase resides in
the ER membrane, consistent with a putative role in the ERAD
pathway. To further confirm our findings, we analyzed
PF14_0215 function by reverse genetics using a double recombi-
nation gene knock out approach (Figure S3). Despite multiple
attempts, we were only able to obtain crossover events at the 39
UTR of PF14_0215 and failed to produce viable parasites with a
disrupted PF14_0215 gene suggesting that PF14_0215 is essential
for parasite survival. This result evokes the observed essentiality of
HRD1 in other eukaryotic model organisms. Evidences showing in
vitro ubiquitylation activity, ER membrane localization, and gene
essentiality strongly suggest that PF14_0215 is the E3 ligase HRD1
Plasmodium homologue of the classical ERAD system.
PFL1245w and PFL0190w are Functional Cytosolic
Ubiquitin Activating and Conjugating Enzymes
PFL1245w and PFL0190w are predicted to be the E1 ubiquitin-
activating enzyme and the E2 ubiquitin-conjugating enzyme,
respectively. In order to validate the in silico predictions, we have
recombinantly cloned, expressed and purified PFL1245w and
PFL1090w (Figure 5A and Figure S1) to test their in vitro activities.
Since we found that PF14_0215 is likely the Plasmodium homologue
of HRD1 of the ERAD system, we also tested the interaction of
PFL1245w and PFL1090w with PF14_0215. Our results show that
recombinant PFL0190w (19.6 kDa) is capable of in vitro mono
(27 kDa band) and di-auto-ubiquitylation (35 kDa band) activity
when incubated with commercially available human UBA1
(Figure 5B, second lane from the right). When the recombinant
PF14_0215 RING domain was added to the reaction, a large
laddering effect (poly-ubiquitin chains) was observed (Figure 5B,
far right lane) similar to the effect observed using the commercial
human UBCH5a (Figure 3B, third lane from the left). Anti-GST
blots further revealed that these poly-ubiquitin chains were
attached to the recombinant GST-tagged RING domain of
PF14_0215 (Figure 5D). In addition, we immunoprecipitated the
endogenous PF14_0215 E3 protein using our custom antibodies
and were able to detect elevated amounts of ubiquitylated
products when incubated in vitro with ubiquitylating reactions,
which included our recombinant full-length PFL0190w E2 protein
(Figure S4). These results show that PFL0190w is a functional E2
ubiquitin-conjugating enzyme that is compatible in vitro with
endogenous PF14_0215.
In vitro ubiquitylation assays were repeated using recombinant
parasite E1 PFL1245w together with E2 PFL0190w and E3
PF14_0215 (Figure 5D). PFL1245w was able to ubiquitylate
PFL0190w as shown by the presence of a band at 27 kDa. When
recombinant Plasmodium E3 ligase PF14_0215 was added to the
reaction, no increase of ubiquitylating activity could be detected.
Considering the mode of action of the classical ERAD-system, it is
possible that the full-length of recombinant PF14_0215 as well as
Figure 1. ERAD inhibitor Eeyarestatin I inhibits P. falciparum in vitro and increases the amount of ubiquitylated Plasmodium proteins.
(A) Eeyarestatin I (ES1) inhibits P. falciparum 3D7 strain with an IC50 value of 3.541561.0399 mM (mean value 6 standard error). Dose-response curve
is plotted with increasing concentrations of ES1 (B) ES1 treatment leads to an accumulation of ubiquitylated proteins in P. falciparum. Anti-ubiquitin
immunoblots show higher levels of ubiquitylated protein levels in P. falciparum parasites when treated with ES1 (lane 2) compared to the control
(DMSO, lane 1). As a comparison, parasite were also treated with proteasome inhibitor MG132 [48] (lane 3) and exhibited slightly higher amounts of
ubiquitylated proteins. When parasites were treated with both ES1 and MG132 (lane 4), significant increases in ubiquitylated products were detected.
doi:10.1371/journal.pone.0043477.g001
Figure 2. Domain architecture of the ubiquitylating components of the Plasmodium ERAD system and cf-C3HC4 domain alignment
of PF14_0215. (A) Proteins are represented as black boxes of length proportional to their sizes in amino acids (aa). SP = signal peptide;
TM = transmembrane domain; ThiF/UBACT = repeats found in E1 ubiquitin-activating enzymes; UBA_e1_C = E1 ubiquitin-activating enzyme catalytic
domain; UQ_con = E2 ubiquitin-conjugating enzyme domain; zf-C3HC4 = E3 ubiquitin ligase RING finger domain. Catalytic cysteines are marked in
yellow. (B) Using MUSCLE [43], we performed protein alignments on PF14_0215 and found that its zf-C3HC4 domain had high homology to other
previously characterized HRD1 of various model systems.
doi:10.1371/journal.pone.0043477.g002
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additional accessory proteins are required for a full in vitro activity
of all three Plasmodium proteins. On the whole, these results
validate (i) PFL1245w as a functional E1 ubiquitin-activating
enzyme that can work in vitro with the E2 PFL0190w, and (ii)
PFL0190w as a functional E2 ubiquitin-conjugating enzyme that
can work in vitro with the E3 ligase PF14_0215.
To further validate PFL1245w and PFL0190w as the likely
Plasmodium ERAD E1 and E2 enzymes, respectively, we investi-
gated their localization using custom-made antibodies; antibody-
specificity was verified by immunoblotting (see Figure S2). In other
model organisms, the classical ERAD E1 UBA1 and E2 UBC7
proteins are reported to reside in the cytoplasm until they are
needed and are recruited to the outer membrane of the ER. Using
immunofluorescence microscopy, we found that both PFL0190w
and PFL1245w are mainly dispersed throughout the cytoplasm
with small aggregations scattered throughout the parasite
(Figures 6A,B). In addition, when PFL1245w was co-immuno-
stained with PMV, an ER membrane marker, there was noticeable
overlap between the two proteins, which suggests that PFL1245w
is likely recruited to the ER membrane as expected (Figure 6C).
The localization pattern of PFL1245w and PFL0190w indicates
cytoplasmic residence with possible transient recruitment to the
ER that is consistent the classical ERAD model. Given their in vitro
activities in auto-ubiquitylating assays and their pattern of
localization, PFL1245w and PFL0190w are likely the Plasmodium
homologues for E1 UBA1 and E2 UBC7 involved in the parasite’s
ERAD system.
Discussion
Proteasome inhibitor studies have shown promising antimalarial
results and have ignited interest in studying how protein
degradation in Plasmodium can be targeted for effective drug
discovery and synthesis. Though there have been several reports
Figure 3. In vitro ubiquitylation assay of PfHRD1 (PF14_0215). (A) Epitope-tagged recombinant PfHRD1 was expressed in E. coli and purified.
Anti-GST immunoblot on purified protein extracts reveals the presence of detached free GST tags (MW = 29 kDa) and of PfHRD1-GST (MW = 42.6 kDa).
(B) In vitro ubiquitylation assays were performed with commercial ubiquitin (Ub), human E1 UBA1, varying human E2 UBC enzymes (i.e., UBCH2,
UBCH3, UBCH5a, UBCH6, UBCH7, UBCH8, UBCH10, and UBCH13), and our purified extract of epitope-tagged recombinant PfHRD1. Ubiquitylation
patterns were revealed on anti-ubiquitin immunoblots. Different patterns of auto-ubiquitylation are observed with UBCH5a, UBCH13, and UBCH6. (C)
In vitro ubiquitylation assays were performed in the presence (+) or absence (-) of commercial ubiquitin (UB), human E1 UBA1, human E2 UBCH5a, and
our purified extract of epitope-tagged recombinant PfHRD. Ubiquitylation patterns were revealed on anti-ubiquitin immunoblots. Ubiquitylation is
specifically observed only when all components are mixed together, including PfHRD1. (D) In vitro ubiquitylation assays were performed with
commercial ubiquitin (Ub), human E1 UBA1, the human E2 enzymes UBCH5a, UBCH6, and UBCH13, and our purified extract of epitope-tagged
recombinant PfHRD1. The attachment of ubiquitin on the recombinant PfHRD1 itself was detected by anti-GST immuno-detection. PfHRD1 is poly-
ubiquitylated in the presence of UBCH5a and mono-ubiquitylated in the presence of UBCH6 whereas UBCH13 does not permit PfHRD1 auto-
ubiquitylation.
doi:10.1371/journal.pone.0043477.g003
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on the efficacy of various proteasome inhibitors on malaria
parasites, there have been relatively few studies done on
functionally characterizing the malarial protein degradation
system upstream of the proteasome. An integral part of protein
degradation within eukaryotic cells is the ERAD system, which
relies on ubiquitylation in order to shuttle misfolded proteins
across the ER membrane and label them for degradation by the
26S proteasome. Here, we show that ESI, a known ERAD
inhibitor, is toxic to the Plasmodium parasite within low mM ranges
and causes increased levels of ubiquitylated products. These results
provide the first indications that an ubiquitin-dependent ERAD
system does exist within the parasite and also gives a proof of
concept that the ERAD system could be a point of antimalarial
drug targeting.
According to our bioinformatics analysis, in vitro ubiquitylation
assays and localization studies, it seems that the Plasmodium ERAD
system may function similarly to that of other eukaryotic model
systems. The domain architecture of these putative ubiquitylating
Plasmodium ERAD proteins are homologues to that of their
identified counterparts in other eukaryotes [21], while localization
studies show them localizing to their expected destinations of
either the ER membrane or cytosol. The in vitro ubiquitylation
assays performed on recombinant versions of PFL1245w,
PFL09190w and PF14_0215 revealed that these proteins are
capable of facilitating ubiquitylation and that they can work
together. In many cases, E3 ligases with RING domains are
known to mediate the transfer of ubiquitin between E2 conjugat-
ing enzymes and target substrates without actually binding to
ubiquitin itself [27]. And though recent studies are reporting novel
RING E3 ligase complexes (e.g. RBR ubiquitin ligases) are capable
of binding to ubiquitin [28], autoubiquitylation of E3 ligases have
been more associated with HECT E3 ligases rather than RING E3
ligases. However, when we experimentally studied the E3 RING
domain of PF14_0215, we found that PF14_0215 was capable of
autoubiquitylation, which is reminiscent to the yeast HRD1p E3
ligase, which has also been reported to autoubiquitylate as a
mechanism to regulate itself [29,30]. All together, our data
indicates that PFL1245w, PFL0190w, and PF14_0215 are the
Plasmodium falciparum UBA1, UBC and HRD1 (PfUBA1, PfUBC
and PfHRD1) respectively and serve to ubiquitylate misfolded ER
proteins for translocation from the ER lumen to the cytosol for
proteasome degradation (see figure 7 for a graphical model).
The results from the knock out attempts of PF14_0215 suggest
that PF14_0215 is an essential Plasmodium gene. As part of the
ERAD system, the probable essentiality of PF14_0215 is not
surprising since the ERAD system, and protein degradation in
Figure 4. Cellular localization of PfHRD1. (A) PfHRD1 and plasmepsin V (PMV), an ER membrane marker, co-localize in P. falciparum. (B) At
various stages of the parasite life cycle, PfHRD1 was co-stained with the nuclei (DAPI) and the apicoplast (ACP-GFP) in the P. falciparum strain D10.
doi:10.1371/journal.pone.0043477.g004
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general, is known to be an essential part of eukaryotic biology.
That is why there is burgeoning interest in proteasome degrada-
tion and inhibitors in regards to antimalarial drug discovery. If the
protein degradation at the proteasome level can be effectively
exploited as a potential antimalarial target, it is reasonable to
believe that upstream pathways, such as the ubiquitylating
components within the ERAD system, may also serve as viable
antimalarial drug targets. Currently, a wide range of ubiquitylating
enzymes, from E1 activating enzymes to deubiquitylating enzymes
(DUB)s are being screened for inhibitors that may confer anti-
cancer properties. In fact, there are already several inhibitors of
ubiquitin or ubiquitin-like enzymes that have shown effective
results against cancer (Sun, 2003; Yang et al, 2007), with some
already in clinical trials (for a review, see [31]).
Some may argue that targeting a highly conserved system such
as the ERAD pathway in the Plasmodium is likely to have cross-
reactivity with the very similar human host ERAD counterpart
and is unlikely to produce a tight parasite-specific drug. However,
inhibitors of ubiquitin E1 enzymes have already been demon-
strated to reduce leukemia and multiple myeloma, while
maintaining limited toxicity in mouse models [32]. The limited
toxicity of E1 ubiquitin inhibitors observed in normal host cells is
likely explained by the notion that inhibition of proteasome
degradation has more of a profound effect on highly proliferative
cells, such as malignant tumors and protozoan parasites, due to
their higher metabolic needs. Furthermore, since it has been
shown that E3 ligases are the most various and divergent within
eukaryotes [21], higher parasite-specificity can be achieved by
targeting essential parasite-specific E3 ligases. Currently, there are
specific inhibitors of E3 ubiquitin ligases that are in clinical trials.
For example, inhibitors of MDM2, the E3 ligase regulator of the
tumor suppressor protein p53, has shown promising anti-myeloma
activity [33]. In theory, components of the Plasmodium ERAD
degradation pathway, particularly its E3 ligases (i.e. SEL1L/
HRD3 [34], gp78 [35], RNF5/RMA1 [36], TEB4/March6 [37]
and TRC8/RNF139 [38]), could produce an effective new
strategy against Plasmodium as they are both specific and likely
essential to the parasite life cycle. Interestingly, there have also
been recent identifications of a duplicated ERAD-like system
within the plastids of some apicomplexans, cryptomonads, and
diatoms [24,25], with P. falciparum included. However, instead of
functioning in protein degradation, the plastid ERAD-like system
is hypothesized to have roles in plastid protein import [39], which
may also turn out to be an effective drug target.
The biology of the Plasmodium ERAD system and overall
degradation pathways are worthy themes to investigate. It will be
Figure 5. In vitro ubiquitylation assay of PfUBA1 and PfUBC. (A) 6xHIS-tagged recombinant PfUBA1 (E1) and PfUBC (E2) are depicted and anti-
HIS blots reveal purification. (B) In vitro ubiquitylation assays were performed with recombinant PfUBC (E2), which revealed an attachment of a single
ubiquitin when incubated with human UBA1 (E1) (second lane from the right) and an increased number of ubiquitylation products when both UBA1
and recombinant PfHRD1(E3) was added (far right lane). (C) When incubated with human UBA1 (E1), recombinant PfUBC (E2) (along with the other
necessary reagents) attaches polymers of ubiquitin to recombinant PfHRD1 (E3) (far right lane). (D) Recombinant PfUBA1 (E1) is capable of attaching a
single ubiquitin to recombinant PfUBC (E2), which is depicted by the appearance of a 27 kDa band (second lane from the right). Extra banding was
not detected with the addition of recombinant PfHRD1 (E3) (far right lane).
doi:10.1371/journal.pone.0043477.g005
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interesting to see whether or not these core ubiquitylating enzymes
do collaborate in conjugating ubiquitin to misfolded proteins in vivo
and work together with other known ERAD proteins (i.e. Der1,
Cdc48, Ufd1) for targeted protein degradation. Also, whether or
not protein degradation in protozoan parasites has unique features
compared to human and yeast models. However, this can only be
uncovered with more targeted and vigilant examination. One
aspect of parasite biology that we can be certain of is that protein
degradation is necessary for parasite survival and has already been
shown to be a good candidate for antimalarial targeting with
reports of proteasome inhibitors conferring Plasmodium IC50 values
within the mM to nM ranges [8]. All together our results show that
the Plasmodium ERAD system offers at least one parasite-specific
drug target candidate, the ERAD E3 ubiquitin ligases, which have
been characterized as being divergent from their human host
counterparts. Though we have just begun to explore the
machinery that is responsible for protein degradation in the
human malaria parasite, we believe that the Plasmodium ERAD
system may provide great drug target candidates that are both
effective and parasite-specific.
Figure 6. Localization studies of PfUba and Pfubc7. (A,B) IFA experiments, using different parasite stages, show that PfUBA1 and PfUBC
localize mainly to the cytosol. (C) When co-immunostained with plasmepsin V (PMV), a Plasmodium ER membrane protein marker, there was
noticeable overlap between the two proteins, suggesting PfUBA1 recruitment to the ER as well.
doi:10.1371/journal.pone.0043477.g006
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Materials and Methods
Half Maximal Inhibitory Concentration (IC50) Assays and
Ubiquitylated Protein Abundance Experiments with
Eeryarestatin I
Eeryarestatin I (ESI) (EMD Millipore Corporation) was
reconstituted at 10 mM in DMSO. 3D7 parasites were introduced
to a 3-fold serial dilution of ESI in complete culture medium in 96-
well plates and incubated for 72 hours in a humid modular
incubation chamber (Billups-rothenberg) after gassing at 1% O2/
3% CO2/96% N2. Plates were frozen overnight then thawed and
evaluated for relative parasite growth with SYBR Green dye and a
Molecular Devices Gemini EM spectrofluorometer.
3D7 parasites were synchronized with sorbitol treatment.
During the early trophozoite stages, parasites were drugged with
either of four different conditions: ESI (10 mM), MG132 (0.1 mM),
ESI (10 mM) + MG132 (0.1 mM) or DMSO only (equivalent
volumes to the drug conditions). After 8 hours incubation,
parasites were isolated with 0.15% saponin and crude protein
lysates were extracted. 0.5 mg of protein lysates from each
condition were loaded in each well for SDS-PAGE. Immunoblots
were probed with rabbit anti-ubiquitin antibodies (Millipore;
1:2500) and goat anti-rabbit antibodies conjugated to HRP
(1:5000; Pierce).
In silico Discovery of Candidate Ubiquitylating Proteins
and Protein Alignments
The translated genome of P. falciparum v8.0 was obtained from
PlasmoDB (www.plasmodb.org) and was bioinformatically
searched to identify ubiquitylating proteins using a previously
published approach [21]. Domain architecture analysis was
performed using InterProScanSequence [40]. Transmembrane
domains were predicted with TMHMM [41]. Signal peptides were
predicted with signal 3.0 [42]. Pictures were generated with
MatlabH. Using MUSCLE [43], we performed protein alignments
on PF14_0215, comparing it to the HRD1 of H. sapien
(BAC24801.1), S. cerevisiae (NP_014630.1), S. pombe
(NP_596376.1) and M. oryzae (XP_003709820.1).
Cloning and Purification of Recombinant Proteins
The plasmid pGS-21a (GenScript) and a modified version of it
(designed as pGS-21aHis) were used as cloning vectors. The region
coding for a GST was removed so that only the two 6xHIS tags
subsist. The GST tag, along with the tandem 6xHIS tag, was
removed by cutting pGS-21a with ClaI and NcoI. A new 6xHis-
coding fragment was then amplified by PCR from purified pGS-
21a using the primers GATCGAGATCGATCTCGATC and
ATCCATGGCCTTACCGCTGCTATGATGATGAT and in-
serted to replace the GST using ClaI and NcoI. The sequence
coding for the RING domain in PF14_0215 was PCR-amplified
Figure 7. Graphical depiction of the Plasmodium ERAD pathway in protein quality control and its potential for antimalarial
strategies. Similar to their human and yeast counterparts, the components of the Plasmodium ERAD system likely serve to recognize and translocate
misfolded ER luminal proteins to the cytosol for degradation by the 26S proteasome. A simplified flowchart is presented: (1) misfolded proteins are
recognized and recruited to the ERAD complex, (2) where they are inserted across the ER membrane through a pore formed by a complex of ERAD
proteins. (3) During translocation, the aberrant proteins are poly-ubiquitylated by the concerted action of the E1 ubiquitin-activating enzyme PfUBA1
(PFL1245w), the E2 ubiquitin-conjugating enzyme PfUBC (PFL0190w), and the E3 ligase PfHRD1 (PF14_0215). (4) The ubiquitylated aberrant proteins
are extracted by the CDC48-UFD1-NPL4 AAA-ATPase complex and shuttled to the 26S proteasome (5) for degradation. Plasmodium ERAD drug target
candidates are highlighted with an orange star.
doi:10.1371/journal.pone.0043477.g007
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from 3D7 strain cDNA using the primers AGGGGATCCCT-
TAAGCCGCGGCCTTTACATATGACAGCAGAT and AG-
GAAGCTTTTAACTAGTGCTAGCTTACTTTTGTGTTG-
TATCATTTTCTG. A sequence segment that contains the E1
ubiquitin-activating domain of PFL1245w was PCR-amplified
using the primers AGGGGATCCCTTAAGCCGCGGGTGGT-
GAATATTTTTGGGTTGG and AGGAAGCTTTTAAC-
TAGTGCTAGCCCAACCCAAAAATATTCACCAC. The en-
tire gene of PFL0190w was amplified from 3D7 strain cDNA with
the primers AGGGGATCCCTTAAGCCGCGGATGGCCCT-
TAAAAGAATAACAAAA and AGGAAGCTTTTAAC-
TAGTGCTAGCTTATTGTGCATATTTTTGTGTCC. The
amplified fragments were digested with SacII and SpeI and
ligated into pGS-21a (6xHis-GST) or pGS-21aHis (6xHis only)
where the gene was N-terminally tagged. Constructs were inserted
into E. coli for expression.
Transformed E. coli cells were grown in LB at 25uC until
OD600.0.5. IPTG 1 mM was added to the cultures, which were
then incubated overnight at 12uC. Cells were collected by
centrifugation at 14,000 g and 4uC and resuspended in lysis
buffer (Tris-HCl pH 7.5 25 mM, NaCl 500 mM, Triton X-100
1% (v/v), Mini EDTA-free Protease Inhibitor Cocktail (Roche),
and AEBSF 1 mM). Cells were sonicated and lysates were cleared
by centrifugation at 14,000 g and 4uC. Purifications of GST-
tagged proteins were performed on glutathione agarose beads
(Sigma-Aldrich). Glutathione-bound proteins were washed three
times with GST wash buffer (Tris-HCl pH 7.5 25 mM, NaCl
300 mM, Triton X-100 1% v/v) and eluted with GST elution
buffer (Tris-HCl pH 7.5 25 mM, NaCl 150 mM, reduced
glutathione 15 mM, Triton X-100 0.01% v/v, glycerol 40% v/
v). Purifications of His-tagged proteins were performed on Ni-
NTA beads (Qiagen). Beads-bound proteins were washed several
times with wash buffer (Tris-HCl pH 7.5 25 mM, NaCl 500 mM,
imidazole 30 mM, glycerol 5% v/v) and subsequently eluted with
elution buffer (Tris-HCl pH 7.5 25 mM, NaCl 500 mM, imidaz-
ole 250 mM, glycerol 5%). Purified protein extracts were analyzed
by immunoblots. GST-tagged proteins were detected using a goat
anti-GST antibody (1:5000; GE Healthcare) and a donkey anti-
goat antibody conjugated to horseradish peroxidase (1:20,000;
Jackson Immuno research). His-tagged proteins were detected
using a mouse anti-His antibody (1:2500; Millipore) and a goat
anti-mouse antibody conjugated to horseradish peroxidase
(1:10,000; BioRad).
Custom Primary Antibodies
The following peptide sequences were used as antigens for the
production of affinity-purified antibodies (Fisher Scientific or
Genscript) in rabbits: RFKSFQKYRELTKNIETK for
PF14_0215, KTDRTKYHQTAKAWTQKYAQ for PFL0190w,
CSDQDLVDVLIPSIQFIYK for PFL1245w.
Parasite Culture and Transfection
The P. falciparum 3D7 (MRA-102, MR4) and D10 ACP(transit)-
GFP (MRA-568, MR4) strains were grown in human O+ red
blood cells according to a previously described protocol [44].
Transfections were carried out by electroporation of parasite-
infected red blood cells as described in [45]. Successful
transfectants were obtained by positive selection with WR99210
[46], and, when relevant, negative selection with 5-fluorocytosine
[47].
Immunofluorescence Assay
Immunofluorescence assays were performed using the protocol
described in [25]. Briefly, cells were washed with PBS and fixed for
1 h at 37uC in PBS containing 4% of paraformaldehyde and
0.0075% glutaraldehyde. Fixed cells were then pelleted by
centrifugation at 700 g for 2 min and washed once for 10 minutes
with glycine 1.25 M in PBS. After another centrifugation at 700 g
for 2 min, the pelleted cells were permeabilized for 10 min with
TritonX-100 0.1% (v/v) in PBS. Permeabilized cells were then
washed once for 10 minutes with glycine 1.25 M in PBS and
pelleted by centrifugation (700 g for x min). After a minimum of a
1 h-long incubation in BSA 3% (w/v) in PBS, the desired target-
specific custom primary antibody was added for at least 2 hours at
room temperature or overnight at 4uC at a dilution of 1:200. Cells
were subsequently extensively washed with PBS. Secondary goat
anti-rabbit IgG Alexa FluorH 488 or donkey anti-rabbit IgG Alexa
FluorH 568 were then added according to their respective primary
antibodies at a dilution of 1:100 for two hours at room
temperature. Cells were washed 3 times with PBS and DAPI
stain was finally added at 100 ng/mL final concentration for nuclei
visualization. Anti-plasmepsin V antibodies (MRA-815A, MR4)
were used to visualize the endoplasmic reticulum membrane [26].
Microscopy slides were mounted with slow-fade mounting
medium (Fluoromount-G; Southern Biotech) and viewed with an
Olympus BX40 fluorescence microscope using a 100X objective
lens (UPlanFI). Image capture was done with a CoolSNAP cf
camera and processed by the Metavue software (Photometrics).
Images were finally merged and background was reduced using
ImageJ software.
In vitro Ubiquitylation Assay
A mix containing free ubiquitin 50–200 mM (Boston Biochem),
Human recombinant UBE1 E1 enzyme 0.05-0.2 mM (Boston
Biochem), Human recombinant UBC E2 enzyme 1–5 mM (Boston
Biochem), and purified Plasmodium E3 ligase 1–12.5 mM was
incubated in reaction buffer (Tris-HCl pH 7.4 50 mM, DTT
1 mM, re-energizing buffer from Boston Biochem) for 2 h at
37uC. Alternatively, Human E1 and/or E2 were replaced with our
purified Plasmodium proteins. Reactions were then analyzed by
SDS-PAGE and anti-ubiquitin or anti-GST immunoblotting.
Anti-ubiquitin immunoblots were probed with rabbit anti-ubiqui-
tin antibodies (1:2500; Millipore) and goat anti-rabbit antibodies
conjugated to HRP (1:5000; Pierce). Anti-GST immunoblots were
probed with goat anti-GST antibodies (1:2500; GE Healthcare)
and donkey anti-goat antibodies conjugated to HRP (1:5000;
Jackson Immunoresearch).
Gene Disruption Experiments
Double recombination-based gene disruption plasmids were
constructed with the 59 UTR and 39UTR of PF14_0215 flanking a
human dihydrofolate reductase (hDHFR) resistance cassette (for
positive selection with WR99210) within the pCC1 vector that also
contains a Saccharomyces cerevisiae cytosine deaminase (ScCD)
cassette for subsequent negative selection [42]. Gene disruption
vectors were transfected into Pf3D7. Successful integration was
verified by PCR.
Immunoprecipitation and in vitro Ubiquitylation Assay of
Pulled-down Proteins
Isolated 3D7 parasites were resuspended in 20 mM HEPES
pH7.9, 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT,
0.5 mM AEBSF (Fisher Scientific), 0.65% Igepal v/v and cocktail
protease inhibitor (Roche) (lysis buffer 1). Parasites were allowed to
lyse on ice for 10 minutes and then were spun down. Supernatant
was collected. The pellet was then subsequently resuspended in
20 mM HEPES pH 7.9, 0.1 M NaCl, 0.1 mM EDTA, 0.1 mM
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EGTA, 1.5 mM MgCl2, 1 mM DTT, 1 mM AEBSF and cocktail
protease inhibitor (Roche) (lysis buffer 2), and then incubated at
4uC with vigorous shaking for 20 minutes. After spinning, the
supernatant was collected. The remaining pellet was then
resuspended in lysis buffer 1 and then sonicated and spun down.
Supernatant was collected and pooled with the previous two
collected supernatants to create a mixture of extracted proteins.
Extracted proteins were precleared with magnetic Protein A beads
(Millipore) and then incubated with anti-PfHRD1 (PF14_0215)
antibodies for 2 hours at 4uC with gentle shaking. Pre-washed
magnetic Protein A beads were added to the samples and allowed
to incubate overnight at 4uC with gentle shaking. Samples were
washed several times with lysis buffer 1. Pulled-down PF14_0215
proteins were left bound to the beads.
Human recombinant UBE1 (Boston Biochem), Plasmodium
recombinant PfUBC (PFL0190w) and pulled-down PfHRD1 were
added to a solution containing 0.2 M HEPES pH7.9, 50 mM
DTT, re-energizing buffer (Boston Biochem), 0.5 mg/mL final
concentration of biotin conjugated ubiquitin (Boston Biochem),
0.5 mg/mL final concentration of ubiquitin (Boston Biochem),
5 mM AEBSF (Fisher Scientific) and cocktail protease inhibitor
(Roche). The reactions were allowed to incubate at 37uC with
gentle agitation for two hours. After incubation, reactions were
terminated with Laemmli buffer and incubated at 95uC for
5 mins. Activity was visualized with affinity blots. Biotin affinity
blots were probed with streptavidin conjugated with peroxidase
(1:10,000; Jackson Immunoresearch). Immunoblot intensities were
measured with ImageJ64 software.
Supporting Information
Figure S1 Coomassie-stained SDS-PAGE gels of puri-
fied recombinant proteins. Coomassie-stained SDS-PAGE
gels show the step-by step purification of recombinant (A)
PF14_0215, (B) PFL1245w, and (C) PFL0190w that have been
either tagged with HIS or with GST and HIS both. In each
elution, a distinguishable band that represents the respective
purified recombinant protein can be found at their expected
molecular sizes: GST-HIS-PF14_0215(249–358 AA), 42.6 kDa;
HIS-PFL1245w (506–799 AA), 41.4 kDa; HIS-PFL0190w (1–
148 AA), 19.6 kDa.
(TIF)
Figure S2 Immunoblots showing custom antibody spec-
ificity. (A) The specificity of the custom-made antibody raised
against PF14_0215 protein (59.8 kDa) was verified by western blot
on crude parasite extract. (B) Using anti-PFL1245w custom
antibodies on crude parasite protein extracts, a band at 131.8 kDa
was detected on an immunoblot, which is the expected size for the
PFL1245w protein. (C) Immunoblots were made using anti-
PFL1245w custom antibodies on crude parasite protein extracts. A
band at 131.8 kDa was detected, which is the expected size for the
PFL1245w protein.
(TIF)
Figure S3 Knock-Out Attempt for PF14_0215. A
PF14_0215 knockout vector was constructed with a human
dihydrofolate reductase (hDHFR) selection cassette that is flanked
by the 59 UTR and 39 UTR of the PF14_0215. A Saccharomyces
cerevisiae cytosine deaminase (ScCD) cassette (not shown) was
placed outside the PF14_0215 59 UTR and 39 UTR sections to be
used for negative selection. Primers (indicated by red arrows) were
designed to only amplify crossover events at either the 59 or 39
UTR of PF14_0215. PCR experiments show that only parasites
that underwent a 39 UTR crossover event, that still leaves the
PF14_0215 intact, could be recovered. Double recombination that
would excise the endogenous PF14_0215 gene was never
recovered.
(TIF)
Figure S4 In vitro ubiquitylation activity of immuno-
precipitated PfHRD1. Using anti-PfHRD1 (PF14_0215) anti-
bodies, endogenous PfHRD1 was immunoprecipitated from 3D7
strains. In vitro ubiquitylation assays were performed using
biotinylated-ubiquitin, thus only newly ubiquitylated products
can be detected with streptavidin blots. Human recombinant
UBE1 (lane 1) by itself was able to produce a single ubiquitylated
product when incubated with biotin-ubiquitin. Aggregates of
biotinylated ubiquitin (depicted by the arrow) were seen in all lanes
(even without the addition of any ubiquitylating enzymes, not
shown) and are considered as background. Recombinant PfUBC
(PFL0190w) (lane 2) and immunoprecitated PfHRD1 (lane 3) by
themselves were unable to produce any ubiquitylated products.
UBE1 and Plasmodium PfUBC together (lane 4) were able to
generate significant levels of newly ubiquitylated products. With
the addition of immunoprecipitated PfHRD1 (lane 5), we were
able to detect around a 44% increased level of ubiquitylation when
compared to lane 4.
(TIF)
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